

# ASCO 2022

## Pre-conference overview

Prepared by: Evaluesserve



# ASCO 2022: Overview

## ASCO 2022 By Numbers



5,000+

Abstracts

400

Exhibitors

120

Abstract sub-categories


85+

Livestream sessions

1

Plenary sessions

## Conference track by subject / issue




Focused theme for current analysis slide#5 onwards

## Key themes emerging from top 4 tracks

### Haematology-Oncology

### Lung Cancer



### Breast Cancer

### Immunotherapy

# Key oncology players' most focussed indications will be breast and lung cancer



> 100 abstracts across indications

Drug	Indication
Trastuzumab deruxtecan	Breast cancer
MEDI5752	RCC, FIH study
Acalabrutinib	CLL
Durvalumab	HCC, biliary tract
Olaparib	Prostate cancer
Osimertinib	NSCLC



Abstracts of six approved and pipeline drugs for >25 cancers

Drug	Indication
Pembrolizumab	TNBC, HCC, bladder cancer, RCC, Cervical cancer, Endometrial cancer, NSCLC, melanoma
Olaparib (with AZ)	Ovarian cancer
Belzutifan	RCC
Lenvatinib	RCC
Favezelimab	cHL
MK-0482	Solid tumours

Merck is expected to highlight significant progress in treating certain **early-stage cancers with pembrolizumab**



Data for > 140 company / investigator-sponsored trials

Drug	Indication
Enasidenib, Nivolumab, Ipilimumab	AML, ESCC, CRC, RCC, MIBC, Melanoma
Pomalidomide, bortezomib, ide-cel, liso-cel	Multiple myeloma, MDS, LBCL
MORAb-202	Ovarian cancer
Nivolumab	NSCLC



~ 130 abstracts across indications

Drug	Indication
Ribociclib	Breast cancer
Alpelisib	Breast cancer
Asciminib	CML
Dabrafenib/ trametinib	Glioma
Lutetium Lu 177	Prostate cancer



18 approved and investigational medicines across >20 indications


Drug	Indication
Glofitamab, Polatuzumab	DLBCL
Mosenutuzumab	FL
Tiragolumab	Lung cancer
Giredestrant, inavolisib	Breast cancer
Entrectinib,	NSCLC

# Top presentation abstracts that created a buzz on social media among oncologists

## Key presentations in ASCO 2022

- **Trastuzumab deruxtecan (T-DXd)** versus treatment of physician's choice (TPC) in patients (pts) with **HER2-low unresectable and/or metastatic breast cancer (mBC)**: Results of **DESTINY-Breast04**, a randomised, phase 3 study.
- Primary results from **TROPiCS-02**: A randomised phase 3 study of **Sacituzumab govitecan (SG)** versus treatment of physician's choice (TPC) in patients with **HR+/HER2- advanced breast cancer**
- Lenalidomide, bortezomib and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed **multiple myeloma (NDMM)**: The phase 3 **DETERMINATION** trial
- A randomised, phase III trial of fulvestrant or exemestane with or without ribociclib after progression or anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients with unresectable or **HR+/HER2- metastatic breast cancer (MBC)**: **MAINTAIN** trial
- Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced **renal cell carcinoma (aRCC)** in **CheckMate 9ER**
- Event-free survival by residual cancer burden after **neoadjuvant pembrolizumab + chemotherapy** versus placebo + chemotherapy for **early TNBC**: Exploratory analysis from **KEYNOTE-522**.

## Novel and remarkable MoAs to be presented in ASCO 2022



Most talked about **KRAS G12C inhibitors** to be presented across indications (NSCLC, CRC, pancreatic cancer and solid tumours) and **novel combinations**

# Pre-conference analysis across key themes

- Haematology-oncology indications
- Lung cancer
- Breast cancer
- Immunotherapy



# Key abstracts from haematology-oncology-related presentations

Wide range of globally developed interesting treatment options along with some provocative results **are** anticipated to be released in ASCO



## Anticipated trends

- **Biologics (~35%)** will be the focus across haematology-oncology presentations
- Among biologics, **mAb and bi-specifics** have emerged as key sub-categories with the maximum anticipated presence
- **Cell and gene therapy (~11%)**-based discussions also seem to be gaining traction



## Spotlight presentations

### Magrolimab Phase Ib data in AML/MDS (5F9005)

Gilead's data for this first-in-class CD47 could reinforce the potential of harnessing the innate immunity of macrophages in MDS and TP53m-AML #7017 and #7020

### Ph1/2 Nirogacestat + low-dose belantamab data in R/R MM DREAMM-5 study

– All eyes on further encouraging data that could potentially enable studies in earlier lines of MM

#443

**Ph3 SHINE study ibrutinib + bendamustine-rituximab data in 1L MCL** – Crucial data to be presented with ~7 year follow up, under Type II review with EMA 1L MCL

#LBA7502

### Ph3 DETERMINATION trial - Lenalidomide, bortezomib, and dexamethasone (RVd) ± ASCT NDMM

– Highly effective and convenient induction regimen combination likely to be game-changing for both transplantation-E/IE MM pts #LBA4

### Updated analysis of Ph3 ECHELON-1: brentuximab vedotin + chemo stage III/IV cHL


– Efficacy and safety results are anticipated to build further on the previous 5-year data demonstrating significant improvement in PFS per INV #7503

### 3 yr follow up data for Ph2 ZUMA-2 trial for KTE-X19 in R/R MCL

– This long-term outcome expected to demonstrate robust clinical activity and manageable safety profile [1-yr follow-up data (n=60) demonstrated ORR 92% and CRR 67%] #7518



## Haematology-oncology tracks



In the 'haematology-oncology section,' the **Lymphoma-focussed sessions are expected to witness maximum presence (~40%)** at ASCO 2022

**Myeloma (25%) and Myeloid (20%) sessions are expected** to have similar presence in the conference

# Key abstracts from lung cancer-related presentations

Mirati's adagrasib and Roche's tiragolumab are riding keen interest from industry experts within lung cancer

## Spotlight presentations in lung cancer

### Practice Changing



- **KRYSTAL-1: Adagrasib in mKARSG12Cm NSCLC & CNS metastases (#9002, #LBA9009)**
- **NADIM II: Neoadjuvant nivolumab + chemo for resectable stage IIIA NSCLC (#8501)** – Perceived SoC potential in chemoimmunotherapy that significantly improves the PR rate of stage 3A NSCLC
- **Surgical Progress in ES-NSCLC: Is Neoadjuvant Therapy the New Standard of Care? (Oral)**

### Shaping the Future



- **CHRYSALIS-2: Amivantamab & lazertinib in EGFRm NSCLC after progression on osimertinib and platinum-based chemo (#9006)** – Exploration of a biomarker-agnostic strategy for heavily pretreated EGFRm NSCLC
- **ATEZO-BRAIN: Atezolizumab + chemo for advanced non-sq NSCLC with untreated brain metastases (#9010)** – Promising intracranial efficacy and safety for underserved segment of patients with brain metastases
- **TACTI-002: Eftilagimod (LAG3) & pembro in 1L mNSCLC (#9003)** – Proof-of-concept evaluation of an immunotherapeutic combination approach discussing advantages of a chemo-free regimen

### Additional Pieces



- **SKYSCRAPER-02: Ph3 study of atezoli+ chemo +/- tiragolumab in 1L ES-SCLC (#LBA8507)** – Anti-TIGIT activity in patient subgroup responding to ICIs? Keenly awaited on any numerical benefit seen and on biomarkers that might suggest reasons for the SCLC failure
- **Outcomes of anti-PDL1 +/- chemo for 1L NSCLC with PD-L1 score  $\geq$  50%: FDA pooled analysis (#9000)** – Would help inform Tx decisions between chemo-immuno and immunotherapy

  
Expert POVs

### KRYSTAL-1

- Amgen's Lumakras (sotorasib) is a first-mover KRAS inhibitor in NSCLC while Mirati's adagrasib is a follower with a differentiated profile (CNS active & in SK111 mutations)
- Adagrasib has comparable response outcomes to sotorasib in NSCLC (ORR 43% vs 37%), though it could be weighed down by QT prolongation
- Adagrasib is viewed to become the preferred KRAS<sup>G12C</sup> inhibitor over time, given CNS metastases activity and overall response in-line with sotorasib


### SKYSCRAPER-02

- Roche experienced a second pivotal failure in lung cancer with SKYSCRAPER-02, the first blow was experienced with the failure of Ph3 SKYSCRAPER-01 in NSCLC (May'22)
- Roche was hoping to continue building on the advances of Tecentriq (approved for SCLC & NSCLC) in difficult-to-treat ES-SCLC, with tiragolumab (anti-TIGIT)
- While ES-SCLC data could be shrugged off as a high-risk venture, failure in NSCLC could read through to the remaining TIGIT programme, eroding away Roche's lead in the class.
- Though Roche is sticking with the drug (and believes two immunotherapies are better than one), there have been ripple effects as iTEOS & GSK evaluating their next steps with belrestotug, in light of Roche's findings
- Data presentation at ASCO will shed insights on TIGIT mechanism for shaping future research

# Key abstracts from breast cancer-related presentations

Experts are excited to see potentially practice-changing results in breast cancer with existing therapies

## Breast cancer perspective



## Spotlight presentations

## Significance

### Change in medical practices

- **Destiny-Breast04:** T-DXd in HER2-low mBC, phase III (#LBA3)
- **TROPiCS-02:** Sacituzumab govitecan in HR+/HER2- advanced breast cancer, phase III (#LBA1001)

- **Registrational data** showing the potential
  - To define a new patient segment for trastuzumab deruxtecan
  - Data in HR+ will add a new indication to saci after TNBC

### Emerging Landscape

- **MAINTAIN & MONALEESA-2:** Ribociclib in HR+/HER2- adv/mBC, phase II & III (#LBA1004, #1017, P395)
- **NeoSTAR:** Sacituzumab govitecan in neoadjuvant TNBC, phase III (#512, P284)
- **Anti-HER3 ADC:** Patritumab deruxtecan in HER3 exp mBC (#1002)

- **Good quality data** with CDK4/6 beyond CDK4/6 progression
- Another opportunity with **ADC treatment** to tailor subsequent therapy
- HER-3 story may be similar to HER2/T-DXd where you need very little expression

### Raising benchmarks

- **Destiny-Breast03:** T-DXd in HER2+ mBC, safety data (#1000)
- **PALOMA-2:** Palbo in ER+/HER2- adv BC, OS data (#LBA1003)
- **FAKTION:** Capivasertib in ER+ BC updated OS, PFS data (#1005)
- **SOLAR-1:** Alpelisib in HR+/HER2- mBC (#1006)
- **KEYNOTE-522:** Pembro in neoadjuvant TNBC (#503)
- **PALLAS:** Palbociclib in HR+/HER2- adjuvant BC (#518)


- **T-DXd now SOC in 2L**, showcasing safety in earlier lines of breast cancer
- Most awaited **OS data with Palbociclib** in 1L breast cancer
- **Residual cancer burden** beyond pCR may be a better estimation of risk in early stage as presented by Keytruda



# Key abstracts from immunotherapy-related presentations


Some of the anticipated data read-outs scheduled at ASCO 2022 could pave way for new era of immunotherapies

## At-a-glance




■ Solid tumor  
■ NSCLC  
■ Others

Data around broad array of mono and combination therapies targeting solid tumours set to be presented



■ CGT  
■ Small Molecule  
■ Biologics  
■ Combo  
■ Others

As anticipated IO focusing biologics program holds greatest presence, CGT observed to strengthen existing position



■ PD-1/L1  
■ Bispecifics  
■ Others

Both as a monotherapy and in combination, the PD-1/L1 mAbs reside strongly at the core of immunotherapy-themed sessions at ASCO'22

## Spotlight presentations

- **First-in-human study data (Ph1) of SRF388 (FC IL-27 targeting) +/- pembro antibody** – While still early, these findings are compelling and support SRF388 potential in the treatment of a variety of tumour types, particularly in combination with other immuno-oncology therapies ([#2501](#))
- **Full data from Ph1 trial evaluating NOUS-209 (off-the-shelf cancer immunotherapy) + pembro in dMMR/MSI-H tumours** – New data from Nouscom's lead asset expected to build further on already reported positive interim safety, immunogenicity and clinical data at SITC'21 and AACR'22 conferences ([#2515](#))
- **Ph1 dose escalation data of MK-0482 (Anti-ILT3 mAb) +/- pembro in advanced solid tumours** – New findings could drive the future for this promising early-stage pipeline asset in Merck's broad portfolio of cancer treatments ([#2505](#))
- **PM8001, a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced STs (Ph1/2a)** – Updated data for China-based firm (Biotheus) could further strengthen existing prelim data indicating manageable safety profile in patients with heavily pre-treated advanced solid tumours ([#2512](#))
- **Improved OS of metastatic cancers in US across all age groups in the immunotherapy era: Implications for considering elderly patients for ICIs** – Targeted to fill gap around population-level data regarding impact of ICIs on the contemporary US cancer pts (included 363,191 pts identified from 2004 to 2018 via SEER database) ([#12039](#))